Courtney D. DiNardo | UT MD Anderson Top Courtney D. DiNardo, M.D., MSCE Department of Leukemia, Division of Cancer Medicine About Dr. DiNardo Dr. DiNardo is a clinical researcher with a specialized focus on prognostication and personalized therapeutics for patients with myeloid …

Michael Andreeff | UT MD Anderson Top Michael Andreeff, M.D., Ph.D. Department of Leukemia, Division of Cancer Medicine About Dr. Andreeff Dr. Andreeff received his M.D. and Ph.D. degrees at the University of Heidelberg, Germany, and additional training and faculty appointments a…

Abstract Glasdegib is a Hedgehog pathway inhibitor. This ongoing, open‐label, phase 2 study ( NCT01546038 ) evaluated glasdegib plus cytarabine/daunorubicin in patients with untreated acute myeloid leukemia (AML) or high‐risk myelodysplastic syndromes (MDS). Patients received gla…

Abstract Somatic mutations in cancer are a potential source of cancer specific neoantigens. Acute myeloid leukemia (AML) has common recurrent mutations shared between patients in addition to private mutations specific to individuals. We hypothesized that neoantigens derived from …

Daniel J. DeAngelo, MD, PhD - Dana-Farber Cancer Institute | Boston, MA Email Daniel J. DeAngelo, MD, PhD Medical Oncology MAKE AN APPOINTMENT Contact Information Office Phone Number 617-582-8410 Fax 617-632-6771 Appointments 617-582-7386 617-632-6028 857-215-3262 (Inpatient Tran…

Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease. Blood Adv. 2026 Mar 10; 10(5):1576-1586. Berman JN, Verma A, Viola S, Alonzo TA , Wang YC, Brodersen LE, Loken M, Beckman A, Hirsch B, Raimondi S, Chisholm KM, M…

Branko Cuglievan | UT MD Anderson Top Branko Cuglievan, MD Department of Pediatrics, Division of Pediatrics About Dr. Branko Cuglievan Dr. Cuglievan completed his Pediatric training in Miami Children's Hospital, and he subsequently completed both Pediatric Hematology and Oncology…

Branko Cuglievan | UT MD Anderson Top Branko Cuglievan, MD Department of Pediatrics, Division of Pediatrics About Dr. Branko Cuglievan Dr. Cuglievan completed his Pediatric training in Miami Children's Hospital, and he subsequently completed both Pediatric Hematology and Oncology…

Branko Cuglievan | UT MD Anderson Top Branko Cuglievan, MD Department of Pediatrics, Division of Pediatrics About Dr. Branko Cuglievan Dr. Cuglievan completed his Pediatric training in Miami Children's Hospital, and he subsequently completed both Pediatric Hematology and Oncology…

Elias Jabbour | UT MD Anderson Top Elias Jabbour, M.D. Department of Leukemia, Division of Cancer Medicine About Dr. Jabbour Dr. Jabbour joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is actively inv…

Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2026 Feb 11; JCO2502083. Pemmaraju N, Marconi G, Montesinos P, Lane AA, Mazzarella L, Sallman DA, Ulrickson ML, Schiller GJ , Erba HP, Wang ES, Walter RB, Deconinck E, Aribi A, Legrand O, Lebon D, M…

Yamamoto JF, Goodman MT . Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008; 19 : 379–390. PubMed Google Scholar Siegel RL, Miller KD, Jemal A . Cancer statistics, 2015. CA Cancer J Clin 2015; 65 …

AI Capone, or the criminal masterminds of the future: The imagined possibilities of malevolent artificial intelligence with an emphasis on money laundering Georgios Pavlidis UNESCO Chair & Jean Monnet Chair, Associate Professor of International and EU Law, Neapolis University Paf…

Undergraduate Courses, Fall 2026 Upper-Division (3000-4000) Note: Course numbers listed in the table are linked to course descriptions below. Class meeting locations are subject to change. Consult the University Registrar for an explanation of the class period abbreviations . Vis…

Finding New Targets for Acute Myeloid Leukemia in Children | Dana-Farber Cancer Institute Skip to content Published: November 2, 2021 Updated: April 2, 2024 Acute myeloid leukemia (AML) is the second most common leukemia diagnosed in children. It is hard to treat and can be fatal…